• No results found

Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug

N/A
N/A
Protected

Academic year: 2020

Share "Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug"

Copied!
7
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Figure 1 Undiscounted (A) and discounted (B) price of the two drug comparators over the model’s time horizon when the comparator drug is already a generic drug.Notes: i: overestimation of the lifetime cost of the new drug; P0: daily price of the generic comparator drug; P1′: daily price of the new drug when considering the future introduction of generic versions of the molecule; P1: daily price of the new drug when ignoring the future introduction of generic versions of the molecule; T1*: timing of the introduction of generic versions of the new drug.
Figure 2 Undiscounted (A) and discounted (B) price of the two drug comparators over the model’s time horizon when both drugs are patented molecules.Notes: i: overestimation of the lifetime cost of the new drug; ii: overestimation of the lifetime cost of the comparator drug; P0’: daily price of the comparator drug when considering the future introduction of generic versions of the molecule; P0: daily price of the comparator drug when ignoring the future introduction of generic versions of the molecule; P1’: daily price of the new drug when considering the future introduction of generic versions of the molecule; P1: daily price of the new drug when ignoring the future introduction of generic versions of the molecule; T0*: timing of the introduction of generic versions of the comparator drug; T1*: timing of the introduction of generic versions of the new drug.
Table 1 incremental cost of dabigatran etexilate compared to generic warfarin when ignoring and when considering the future introduction of generic dabigatran etexilate
Table S1 Base case parameters for the case study

References

Related documents

Nurse Hazel develops a plan of care for the client and determines that which of the following nursing actions is the prioritya. Nurse Oliver is teaching a diabetic pregnant

Currently, National Instruments leads the 5G Test & Measurement market, being “responsible for making the hardware and software for testing and measuring … 5G, … carrier

My understanding of the importance of China's image and representation in the political economic goals of the Party impacts how I view the function of the projected national

Considering that a large portion of research datasets (and associated research funding) are found in the long tail, it is paramount that we address the specific and unique

In this paper it will be argued that a compositional meaning theory can be given through a proof-theoretic semantics which is able to justify all inferences of classical

Goldfish care Planning your aquarium 4-5 Aquarium 6-7 Equipment 8-11 Decorating the aquarium 12-15 Getting started 16-17 Adding fish to the aquarium 18-19 Choosing and

Although all our member centers provide space for various 12 step meetings and other peer to peer recovery supports – recovery centers are not affiliated with any of these groups..

If you want to remove all Virtual Server settings from the table, just click the "Delete All" button.. Click "Reset" will clear your